» Articles » PMID: 28424281

Distinct Roles of Vaccinia Virus NF-κB Inhibitor Proteins A52, B15, and K7 in the Immune Response

Overview
Journal J Virol
Date 2017 Apr 21
PMID 28424281
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Poxviruses use a complex strategy to escape immune control, by expressing immunomodulatory proteins that could limit their use as vaccine vectors. To test the role of poxvirus NF-κB pathway inhibitors A52, B15, and K7 in immunity, we deleted their genes in an NYVAC (New York vaccinia virus) strain that expresses HIV-1 clade C antigens. After infection of mice, ablation of the , , and genes increased dendritic cell, natural killer cell, and neutrophil migration as well as chemokine/cytokine expression. Revertant viruses with these genes confirmed their role in inhibiting the innate immune system. To different extents, enhanced innate immune responses correlated with increased HIV Pol- and Gag-specific polyfunctional CD8 T cell and HIV Env-specific IgG responses induced by single-, double-, and triple-deletion mutants. These poxvirus proteins thus influence innate and adaptive cell-mediated and humoral immunity, and their ablation offers alternatives for design of vaccine vectors that regulate immune responses distinctly. Poxvirus vectors are used in clinical trials as candidate vaccines for several pathogens, yet how these vectors influence the immune system is unknown. We developed distinct poxvirus vectors that express heterologous antigens but lack different inhibitors of the central host-cell signaling pathway. Using mice, we studied the capacity of these viruses to induce innate and adaptive immune responses and showed that these vectors can distinctly regulate the magnitude and quality of these responses. These findings provide important insights into the mechanism of poxvirus-induced immune response and alternative strategies for vaccine vector design.

Citing Articles

Neutrophils in oncolytic virus immunotherapy.

Zhou D, Zhang C, Sun J, Yuan M Front Immunol. 2024; 15():1490414.

PMID: 39697335 PMC: 11652357. DOI: 10.3389/fimmu.2024.1490414.


Vaccinia Virus: Mechanisms Supporting Immune Evasion and Successful Long-Term Protective Immunity.

Hsu J, Kim S, Anandasabapathy N Viruses. 2024; 16(6).

PMID: 38932162 PMC: 11209207. DOI: 10.3390/v16060870.


Rendezvous with Vaccinia Virus in the Post-smallpox Era: R&D Advances.

Wang Y Viruses. 2023; 15(8).

PMID: 37632084 PMC: 10457812. DOI: 10.3390/v15081742.


Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review.

Li M, Zhang M, Ye Q, Liu Y, Qian W Cancer Biol Med. 2023; 20(9).

PMID: 37615308 PMC: 10546091. DOI: 10.20892/j.issn.2095-3941.2023.0202.


Improving poxvirus-mediated antitumor immune responses by deleting viral cGAMP-specific nuclease.

Riederer S, Del Canizo A, Navas J, Peter M, Link E, Sutter G Cancer Gene Ther. 2023; 30(7):1029-1039.

PMID: 37016144 PMC: 10353925. DOI: 10.1038/s41417-023-00610-5.


References
1.
Gomez C, Najera J, Krupa M, Perdiguero B, Esteban M . MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther. 2011; 11(3):189-217. DOI: 10.2174/156652311795684731. View

2.
Yang O, Daar E, Ng H, Shih R, Jamieson B . Increasing CTL targeting of conserved sequences during early HIV-1 infection is correlated to decreasing viremia. AIDS Res Hum Retroviruses. 2010; 27(4):391-8. PMC: 3101083. DOI: 10.1089/aid.2010.0183. View

3.
Mooij P, Koopman G, Drijfhout J, Nieuwenhuis I, Beenhakker N, Koestler J . Synthetic long peptide booster immunization in rhesus macaques primed with replication-competent NYVAC-C-KC induces a balanced CD4/CD8 T-cell and antibody response against the conserved regions of HIV-1. J Gen Virol. 2015; 96(Pt 6):1478-1483. DOI: 10.1099/vir.0.000074. View

4.
Harari A, Bart P, Stohr W, Tapia G, Garcia M, Medjitna-Rais E . An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med. 2008; 205(1):63-77. PMC: 2234371. DOI: 10.1084/jem.20071331. View

5.
Thapa M, Welner R, Pelayo R, Carr D . CXCL9 and CXCL10 expression are critical for control of genital herpes simplex virus type 2 infection through mobilization of HSV-specific CTL and NK cells to the nervous system. J Immunol. 2008; 180(2):1098-106. PMC: 2185792. DOI: 10.4049/jimmunol.180.2.1098. View